Gene Therapies For Cardiomyopathies Pipeline Insight

DelveInsight’s, “Gene Therapies For Cardiomyopathies Pipeline Insight, 2026” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Gene Therapies For Cardiomyopathies pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Gene Therapies For Cardiomyopathies Understanding

Gene Therapies For Cardiomyopathies Overview

Gene therapies for cardiomyopathies represent an emerging and highly promising therapeutic approach aimed at addressing the underlying genetic and molecular causes of heart muscle disorders rather than merely managing symptoms. Cardiomyopathies are a heterogeneous group of diseases characterized by structural and functional abnormalities of the myocardium, including hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), restrictive cardiomyopathy, arrhythmogenic cardiomyopathy, and certain metabolic or mitochondrial cardiomyopathies. Many of these conditions are inherited and arise from mutations in genes encoding sarcomeric proteins, cytoskeletal proteins, ion channels, mitochondrial proteins, or components involved in calcium handling and cardiac contractility.

The development of gene therapies for cardiomyopathies has been enabled by advances in molecular genetics, viral vector engineering, and genome editing technologies.

Adeno-associated virus (AAV) vectors, particularly cardiotropic serotypes such as AAV9, are widely used because of their ability to efficiently target cardiomyocytes with relatively low immunogenicity and long-term transgene expression. Different therapeutic strategies are under investigation depending on the disease mechanism. Gene replacement therapy introduces a healthy copy of a defective gene in loss-of-function disorders, while gene silencing approaches using RNA interference (RNAi), antisense oligonucleotides (ASOs), or microRNA modulation are employed to suppress toxic gain-of-function mutations. Genome editing technologies such as CRISPR-Cas9, base editing, and prime editing are also being explored to precisely correct disease-causing mutations at the DNA level.

The therapeutic applications of gene therapies for cardiomyopathies span a wide spectrum of inherited and acquired heart muscle disorders, each tailored to the specific genetic defect and disease mechanism. In HCM, most commonly caused by gain-of-function mutations in sarcomeric genes such as MYH7 and MYBPC3, gene silencing strategies using RNAi or ASOs are being developed to suppress the expression of the mutant allele, thereby reducing sarcomeric hypercontractility, myocyte disarray, and left ventricular hypertrophy. For DCM, which often arises from loss-of-function mutations in genes encoding cytoskeletal proteins like TTN or LMNA, gene replacement therapy using AAV vectors aims to restore the missing protein, improving nuclear integrity, force transmission, and contractile function. In arrhythmogenic cardiomyopathy (ACM), typically linked to mutations in desmosomal genes such as PKP2 (plakophilin-2), gene replacement has shown promise in preclinical models by re-establishing desmosomal adhesion, reducing fibro-fatty replacement, and suppressing life-threatening ventricular arrhythmias.

Beyond these primary cardiomyopathies, gene therapy is also being applied to systemic disorders with cardiac involvement: in Duchenne muscular dystrophy (DMD)-associated cardiomyopathy, micro-dystrophin delivery via AAV or exon-skipping approaches preserves cardiac and skeletal muscle function; in Fabry disease, gene therapy seeks to provide a functional copy of the GLA gene to restore α-galactosidase activity and prevent glycosphingolipid accumulation in cardiomyocytes; and in Danon disease, caused by LAMP2 deficiency, clinical trials of AAV-mediated gene replacement have demonstrated early safety signals and biochemical improvements. Additional applications include targeting calcium-handling proteins like SERCA2a in end-stage heart failure to enhance sarcoplasmic reticulum calcium reuptake, as well as using CRISPR-Cas9 and base editing to permanently correct mutations in metabolic or mitochondrial cardiomyopathies. Collectively, these diverse applications illustrate how gene therapy platforms whether replacement, silencing, editing, or modulation are being strategically matched to distinct genetic etiologies, advancing a paradigm of precision medicine for cardiomyopathy patients.

"Gene Therapies For Cardiomyopathies Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gene Therapies For Cardiomyopathies pipeline landscape is provided which includes the disease overview and Gene Therapies For Cardiomyopathies treatment guidelines. The assessment part of the report embraces, in depth Gene Therapies For Cardiomyopathies commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gene Therapies For Cardiomyopathies collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Discover the latest Gene Therapies for Cardiomyopathies pipeline insights, emerging therapies, and clinical advancements shaping the future of treatment in 2026.

Gene Therapies For Cardiomyopathies Pipeline Report Highlights

The Gene Therapies For Cardiomyopathies companies and academics are working to assess challenges and seek opportunities that could influence Gene Therapies For Cardiomyopathies R&D. The therapies under development are focused on novel approaches to treat/improve Gene Therapies For Cardiomyopathies.

Gene Therapies For Cardiomyopathies Emerging Drugs Analysis

This segment of the Gene Therapies For Cardiomyopathies report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Gene Therapies For Cardiomyopathies Emerging Drugs

Nexiguran ziclumeran (nex-z): Intellia Therapeutics

Nexiguran ziclumeran (nex-z, formerly NTLA-2001) is an investigational, one-time CRISPR/Cas9 gene-editing therapy designed to treat transthyretin (ATTR) amyloidosis by inactivating the TTR gene in the liver. It is being developed by Intellia Therapeutics and Regeneron. Early Phase I studies show it deeply and durably reduces harmful TTR protein levels, with potential to serve as a, long-lasting treatment. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Transthyretin Amyloidosis (ATTR) With Cardiomyopathy.

LX2020: Lexeo Therapeutics

LX2020 is a gene therapy candidate designed to deliver a fully functional PKP2 gene to cardiac muscle for the treatment of PKP2-ACM. PKP2 mutations are associated with approximately 75% of all genetic cases of ACM, and we estimate they affect approximately 60,000 patients in the United States. PKP2 mutations can cause replacement of heart muscle with fibrotic tissue and fatty deposits, and severe abnormal heart rhythms, or arrhythmias, that cause cardiac dysfunction and can result in sudden cardiac death. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Arrhythmogenic Cardiomyopathy.

RP-A701: Rocket Pharmaceuticals Inc.

RP-A701 is an investigational gene therapy for the treatment of BAG3-associated Dilated Cardiomyopathy (BAG3-DCM), an inherited heart disease caused by mutations in the BAG3 gene. The genetic mutation leads to an accumulation of misfolded and damaged proteins, which can impair the heart’s ability to contract, causing impaired cardiac function, heart failure, and even premature death. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Dilated Cardiomyopathy (DCM).

Further product details are provided in the report……..

Gene Therapies For Cardiomyopathies Drug Therapeutic Assessment

This segment of the report provides insights about the different Gene Therapies For Cardiomyopathies drugs segregated based on following parameters that define the scope of the report, such as:

Major Gene Therapies For Cardiomyopathies Players in Gene Therapies For Cardiomyopathies

There are approx. 18+ key companies which are developing the therapies for Gene Therapies For Cardiomyopathies. The companies which have their Gene Therapies For Cardiomyopathies drug candidates in the most advanced stage, i.e. Phase III include, Intellia Therapeutics.

Gene Therapies For Cardiomyopathies Clinical Trial Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Gene Therapies For Cardiomyopathies Drug Route of Administration

Gene Therapies For Cardiomyopathies pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Gene Therapies For Cardiomyopathies Product Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Gene Therapies For Cardiomyopathies Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Gene Therapies For Cardiomyopathies Clinical Trial Activities

The Gene Therapies For Cardiomyopathies pipeline report provides insights into different Gene Therapies For Cardiomyopathies clinical trials within phase II, I, preclinical and discovery stage. It also analyses Gene Therapies For Cardiomyopathies therapeutic drugs key players involved in developing key drugs.

Gene Therapies For Cardiomyopathies Pipeline Development Activities

The Gene Therapies For Cardiomyopathies clinical Trial analysis report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gene Therapies For Cardiomyopathies drugs.

Gene Therapies For Cardiomyopathies Pipeline Report Insights

• Gene Therapies For Cardiomyopathies Pipeline Analysis
• Gene Therapies For Cardiomyopathies Therapeutic Assessment
• Gene Therapies For Cardiomyopathies Unmet Needs
• Impact of Gene Therapies For Cardiomyopathies Drugs

Gene Therapies For Cardiomyopathies Pipeline Report Assessment

• Gene Therapies For Cardiomyopathies Pipeline Product Profiles
• Gene Therapies For Cardiomyopathies Therapeutic Assessment
• Gene Therapies For Cardiomyopathies Pipeline Assessment
• Gene Therapies For Cardiomyopathies Inactive drugs assessment
• Gene Therapies For Cardiomyopathies Market Unmet Needs

Discover actionable insights into Gene Therapies for Cardiomyopathies market trends, epidemiology trends, and forecast through 2036 to stay ahead in emerging therapies.

Key Questions Answered In The Gene Therapies For Cardiomyopathies Pipeline Report:

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Gene Therapies For Cardiomyopathies drugs?
• How many Gene Therapies For Cardiomyopathies drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Gene Therapies For Cardiomyopathies?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Gene Therapies For Cardiomyopathies therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Gene Therapies For Cardiomyopathies and their status?
• What are the key designations that have been granted to the emerging drugs?

Gene Therapies For Cardiomyopathies Key Players

• Intellia Therapeutics
• Lexeo Therapeutics
• Rocket Pharmaceuticals Inc.
• Sardocor Corp.
• Tenaya Therapeutics
• Affinia Therapeutics
• Nuevocor
• AskBio Inc
• Solid Biosciences
• AstraZeneca

Gene Therapies For Cardiomyopathies Key Products

• Nexiguran ziclumeran (nex-z)
• LX2020
• RP-A701
• SRD-001
• TN-401
• AFTX-201
• NVC-001
• AB-1002
• SGT-601
• ALXN2350

Explore comprehensive insights into Gene Therapies For Cardiomyopathies epidemiology trends, patient population forecasts, and growth opportunities through 2034 for strategic decision-making.